This is the authors' abstract. We don't add key points for this paper.
According to the current practice guideline released on 10/29/24, most patients can continue GLP-1 RA therapy perioperatively; however, point-of-care ultrasound (POCUS) examinations have found solids or liquids retained in their stomachs despite adherence to this recommendation. While the guideline aims to streamline perioperative care, it may inadvertently increase anesthesia risk in certain patients. This paper demonstrates that many patients retain stomach contents despite discontinuing GLP-1 RA therapy for up to two weeks, and proposes a new dosing strategy to minimize anesthetic aspiration risk while limiting therapy interruption. Geometric series, exponential decline, and pharmacokinetic principles were applied to develop this schedule, based on the premise that medications are considered cleared after approximately four half-lives. Since the half-lives of semaglutide and liraglutide are approximately one week and 13 hours, respectively, we propose switching patients from semaglutide to liraglutide four weeks before surgery, then discontinuing liraglutide two days before surgery — timing that allows medication levels to decline by the full four half-lives. This strategy minimizes residual drug levels, reduces gastric retention, and lowers aspiration risk, all while limiting the overall interruption of GLP-1 RA therapy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Beisel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: